Abstract Breast cancer is among the most common tumors affecting women. It is characterized by a number of genetic aberrations. Some 5-10% of cases are thought to be inherited. The hereditary breast and ovarian cancer syndrome includes genetic alterations of various susceptibility genes, particularly BRCA1 and BRCA2. Breast tumors of patients with germ-line mutations in the BRCA1 and BRCA2 genes have more genetic defects than sporadic breast tumors. Here we review new findings in the function of BRCA1 gene function. Accumulation of somatic genetic changes during tumor progression map follows a specific and more aggressive pathway of chromosome damage in these individuals. A major BRCA1 downstream target gene is the DNA damage-responsive gene
Introduction
Since inherited genetic factors make a minor contribution to susceptibility to most types of neoplasm, the environment must play a crucial role in causing sporadic cancer. However, the relatively large effect of heritability in some types of cancer at only a few sites (prostate, colon, thyroid, breast) suggests the presence of major gaps in our knowledge of the genetics of cancer [1] . Breast cancer is one of the most common tumors affecting women. Approximately 5-10% are thought to be inherited. The hereditary breast and ovarian cancer syndrome includes genetic alterations in various susceptibility genes such as p53, ATM, PTEN or MSH2, MLH1, PMS1, PMS2, MSH3, MSH6, BRCA1, and BRCA2.
Not only genetic but also epigenetic events may be important in the development of breast cancer. Cancer cells often exhibit an aberrant methylation of gene promoter regions, tightly linked to the formation of transcriptionally repressive chromatin. This phenomenon is associated with loss of gene function. Such epigenetic processes act as an alternative to mutations of tumor-susceptibility genes, and they can predispose to genetic alterations by the inactivation of DNA-repair genes. Dissecting the molecular processes included in these methylation changes will enhance our understanding of chromatin modeling and gene regulation. Methylation changes constitute potentially sensitive molecular markers to define risk status, suggest monitor prevention strategies, and achieve early diagnosis and track prognosis of cancer [2] .
Dietary patterns nutrients and other constituents of food are major components of the environmental influences that contribute to the risk of cancer. The study of interactions between nutritional and genetic factors as well as molecular mechanisms of nutriceutical action is a new and important area of research [3] . Polymorphisms exist in the genes coding for the activating and conjugating metabolizing enzymes; induction of metabolizing enzyme activity by nutritional factors may result in either the activation of a carcinogen or the detoxification of a reactive intermediate metabolite. An example of a dietgene interaction that involves a genetic polymorphism in vitamin metabolism is the relationship between the methylene tetrahydrofolate reductase gene and dietary folate; the presence of the variant appears to influence both the risks for cancer and folate requirements. Increased knowledge in this area will allow a more refined approach in order to reduce risk of cancer, especially in those individuals and subgroups who are genetically susceptible and responsive to the influence of nutritional factors [4] .
Recent advances in genomics and bioinformatics will help in target identification, in particular high-throughput DNA sequencing approaches and differential gene expression profiling using high-density microarrays. Advances in high-throughput screening, combinatorial chemistry, rational drug design (peptide mimetic), and structural biology will facilitate identification of small molecules involved in pathological process.
New understanding of BRCA1 function
In some cases breast cancer exhibits familial clustering suggestive of a significant inherited component. Among important genes known to be related to susceptibility for cancer are those dominant genes conferring a high risk of breast and ovarian cancer (BRCA1 and BRCA2). In recent years the rapid increase in the number of sequenced human genes and combined use of genomics and arraybased expression analysis as well as better understanding of many signal transduction pathways has led to a dramatic expansion of knowledge about the number of potential cancer targets which include both BRCA1 and BRCA2 genes [5] .
The two genes have a similarly complex genomic structure. BRCA1 is composed of 24 exons and BRCA2 of 27. In both, exon 1 is noncoding and exon 11 is unusually large: 3.4 kb in BRCA1 and 5 kb in BRCA2. Both genes encode very large proteins; BRCA1 consist of 1863 amino acids and BRCA2 of 3418. Proteins are present in a wide range of tissues and show remarkably similar temporal and spatial patterns of occurrence. "Knock-out" mouse mutants for BRCA1 and BRCA2 share similar phenotype; embryonic lethality occurs in the stage of early development. The developing embryos show signs of a cellular proliferation defect associated with activation of p53 pathway [6] .
BRCA1-associated hereditary breast cancers are frequently ductally invasive, high-grade carcinomas with an abundant lymphocyte infiltration. They are aneuploid, estrogen and progesterone receptor negative, and p53 positive. BRCA2-related breast cancers tend to be higher grade tumors than nonhereditary cases. These tumors exhibit substantially less tubule formation, but mitotic count and cellular pleomorphism do not differ significantly from those of sporadic tumors. The overall pattern of the identified pathological characteristics suggests the presence of a similar neoplastic pathways in both BRCA1-and BRCA2-related breast cancers which are different from those found in sporadic cases [7] .
The protein product of the BRCA1 gene is implicated in the cellular response to DNA damage, with postulated roles both in homologous recombination and in tran-scriptional regulation. During S phase the endogenous wild-type protein is present within nuclear dots, partially colocalized with RAD51, the mammalian homologue of bacterial recA that is involved in repair of double-strand breaks in DNA following ionizing radiation [8] . BRCA1 may influence a cell cycle checkpoint by inducing a dephosphorylation of pRb, making the protein "active" by allowing it to bind E2F and thereby inhibit progression into S phase. This action seems to be closely connected with inhibition of cdk2 activity [9] .
A distinct role for BRCA1 has been proposed in transcriptional regulation. BRCA1 increases p53-dependent and independent transcription from the p21 WAF1/CIP1 and box promoters [10, 11] . Moreover, BRCA1 and p53 proteins interact both in vivo and in vitro [12] . Tumor-derived transactivation-deficient BRCA1 mutants are defective in coactivation of p53-dependent transcription and a truncation mutant of BRCA1 that retains the p53-interacting region acts as a dominant inhibitor of p53-dependent transcription. BRCA1 coelutes with the RNA polymerase II holoenzyme complex, and it may interact with RNA helicase and the transcriptional regulators p53, CtIp, and c-Myc [13, 14, 15] . BRCA1 and p53 may coordinately regulate gene expression in their role as tumor suppressors (Fig. 1) . BRCA1 has therefore been implicated in genomic stability, by mechanisms that may involve both transcriptional regulation and the maintenance of chromosomal integrity.
Two categories of genes are significantly altered in BRCA1 transfected cells: cell cycle control genes and DNA damage response genes. Interestingly, expression of the genes involved in signal transduction, cell adhesion, and angiogenesis remain unchanged upon transfection [9] . A major target is the DNA damage-responsive gene GADD45. Induction of BRCA1 triggers apoptosis by activation of c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) a signaling pathway potentially linked to GADD45 gene family members. Induction of GADD45 expression and JNK/SAPK-dependent apoptosis has been shown to be p53 independent [16] . Additionally, MacLachlan and coworkers have found in several cell lines that proliferating-cell nuclear antigen, RhoA, insulin-like growth factor (IGF) binding protein 4, and catenin are upregulated by BRCA1. They also found, in contrast with Harkin, a lack of apoptosis and repression of the apoptosis inducer Bax in tested cell culture lines. These data support the hypothesis that the effects on apoptosis vary by cell type [9, 16] .
There is new evidence for a role of BRCA1 in transcription control. Bochar and colleagues [17] and Sudarsanam and Winston [18] have reported that BRCA1 interacts with a multiprotein human chromatin remodeling complex -the SWI/SNF -which controls DNA organization and provides a mechanism by which BRCA1 regulates transcription by modulating chromatin structure. It will be interesting to screen families with hereditary breast cancer but who have no mutations in either BRCA1 or BRCA2, as well as sporadic breast tumors for the presence of mutation in those genes/proteins which have been shown to be included in regulation of BRCA1 function (i.e., kinase Chk2 and members of SWI/SNF complex, mainly BRG-1) [19, 20] .
Impact of the human genome project and DNA microarrays
Major breakthroughs are expected from our knowledge obtained in the human genome project and differential gene expression profiling using high-density microarrays. Human genome studies and the development of DNA microarrays (or "DNA chips"), a powerful new Fig. 1 Possible biological pathways of BRCA1 protein [9, 10, 11, 12, 16, 17, 40, 41, 45] . MAPKK Mitogen-activated protein kinase kinase technology that provides a window for observing patterns of gene activity in cells, are expected to improve cancer classification [21] .
Pathologists' traditional tumor classification relies on subjective judgements of tumor histology. This approach very often does not permit distinguishing between tumors with similar histopathological features but different clinical course and response to a given treatment. Comprehensive profiles of the molecular alterations in tumors will help to identify distinct subset of patients. The molecular portraits of individual breast tumors will also provide us with clues about the details of molecular machinery in cancer cells and this should allow us to design therapy that is targeted to that aspect of the molecular mechanisms responsible for cancer.
DNA microarray technology implementing the Human Genome Project data allows researchers to compare the activity and interaction of all expressed genes at once. Monitoring global gene expression provides an opportunity to obtain information on complex systems in cells and initiate entirely new fields of investigation. Researchers will find out what appears to be the common characteristic of tumors with distinctive molecular profiles which will than "annotate" these profiles with the relevant clinical data -such as tumor stage and grade, demographic data, response to therapy, and prognosis. New statistical models for handling the massive data will be required to utilize these data effectively. Microarray analysis also provides valid classification information about breast cancers and the cell type expression profile that make them up.
The recent study by Perou et al. [22] identified a cluster of genes that classifies a subgroup of tumors not recognized by the currently available pathological techniques. The ability to distinguish morphologically similar human cancers by the difference in their expression profiles is extremely important because accurate identification of tumor types facilitates matching the appropriate therapies, thereby maximizing therapeutic efficacy and minimizing toxicity.
Complementary DNA microarrays represent several thousand expressed human genes which provide a distinctive molecular portrait of each tumor. Perou and colleagues [22] analyzed 8102 expressed human genes in breast cancer before and after a 16-week course of doxorubicin chemotherapy. The largest distinct cluster of genes (1753/8102, 22%) made a "proliferation cluster." Their expression was well correlated with cellular proliferation, and their expression varied widely between tumor samples and was generally well correlated with the mitotic index. Several groups of coexpressed genes provided views of the activities of specific signaling and/or regulatory systems. Gene expression patterns in two tumor samples from the same individual were almost always more similar to each other than to any other sample [22] . Authors could recognize the distinctive gene expression pattern of a tumor in independent samples suggesting that molecular portraits faithfully represent the "tumor itself" and not merely the particular tumor "sample." However, gene expression analysis can identify only activated or deactivated genes. Such genes must then be confirmed concerning their function, which is time consuming and difficult.
In addition to microarray analysis, there are other ways for detecting of genetic changes in breast cancer. One of these is comparative genomic hybridization. Loveday and coworkers [23] screened breast carcinomas for copy number changes using comparative genomic hybridization. A number of loci not previously shown to have undergone frequent change were identified. These included gene copy number gains affecting chromosomes 1p, 4q, 5q, 6q, and 13q. Two regions of copy number change also were identified; a gain on 5p and deletion of 16q, the latter correlated with lobular breast carcinomas. These results highlight several areas of the genome that may be important in the molecular genetics of breast cancer.
Postgenomic era: proteomics
The availability of fully sequenced genomes and the enormous amount of data on coexpression of mRNAs open a new way to analyze proteins on a large scale, which will greatly contribute to our understanding of gene function in the postgenomic era [24] . The largescale study of proteins is called proteomics, the discipline completely complementary to genomics. Proteomics is needed to establish valuable links in studying genes and genomes; the existence of an open reading frame in genomic data does not necessarily imply the existence of a functional gene. It is sometimes still difficult to predict gene function from a genome database. The success rate for correct prediction of primary protein structure is still low, particularly in the case of small genes and genes with little or no homology to other known genes. Modulations of the proteins that are not apparent from the DNA sequence, such as isoforms and posttranslational modifications, can be determined only by proteomic methods. Proteomics focuses on the gene products, which are the active molecules in cells. For this reason proteomics directly contributes to drug development, which is already of great importance in cancer therapy and will be even more important in the very near future.
Proteomics in breast cancer biology as well as in the other fields can be divided into three main areas: (a) protein microcharacterization for large-scale identification and their posttranslational modifications, (b) "differential display" proteomics for comparison of protein levels with potential application in a wide range of diseases, and (c) studies of protein-protein interactions. Indeed, each protein in a living organism functions as a part of an extended network of interacting molecular "partners" [25] .
The first applications of proteomics to benefit cancer will probably be in the area of early diagnostics. An ultimate goal in breast cancer research is to develop a rela-tively simple diagnostic test which will give an interpretable result in the earliest phase of pathological process based on determination of protein expression profiles to identify those proteins that are differentially expressed in breast cancer cells. Because cells change their protein expression pattern significantly when they are cultured, only biopsy material should be used. However, due to low level of differentially expressed protein in this approach, it will be of great importance to improve the sensitivity of the proteomics methods, mainly two-dimensional gel electrophoresis and MALDI-MS.
A possible scenario of the future might be analysis of a large number of biopsy samples in persons at risk in order to identify those lesions that are most likely to develop into malignant tumors. It will be necessary to follow many patients with the same type and grade of carcinoma for a long time. Any protein that is differentially expressed in targeted tissue could be a prospective tumor marker. So far the sensitivity of the method is relatively low for finding the interesting low abundant proteins which may become drug targets. Meaningful data will be obtained only if proteomics is used in accurately defined systems.
Genetic testing
Progress in the past 5 years has offered the possibility of a molecular test for genetic screening for inherited mutations of cancer predisposing genes. Identification of inherited cancer syndromes, predictive genetic testing, and genetic counseling of persons who are at increased risk is of a great clinical importance [26] . There will probably never be a single test that can detect the predisposition to all kinds of tumor. However, presuming that each cancer has its own molecular portrait [22] , it may be expected that a comprehensive genetic test in the future (perhaps DNA microarrays) will by applied to small biopsy specimens. It is obvious that an understanding of a "genetic portrait" will become increasingly relevant in the management of persons who develop breast as well as other types of cancer. At the moment we are able to use the conventional molecular genetic approach based on detection of mutation in known susceptibility genes [27] .
Nevertheless, debate surrounding presymptomatic diagnostic testing and adequate programs for early cancer detection, prevention, and clinical follow-up continues. Twenty to 30% of all women with breast cancer have at least one affected relative; individuals with inherited BRCA1 or BRCA2 mutations can now have more accurate risk assessment with genetic testing. Genetic counseling and identification of high-risk families may be essential to: (a) provide the best method for genetic testing by explaining the sensitivity and specificity of the methods, (b) offer an opportunity to participate in specific early cancer detection programs, (c) inform them about prophylactic medication, chemoprevention, and surgery, and (d) provide individualized psychological support [28] .
If genetic tests to detect persons at risk of breast cancer are to be incorporated into future prevention programs, evaluation is needed of whether the testing can have the intended effect [29] . Various issues should be first considered, including: (a) individual risk assessment and gain in life expectancy, (b) the value of screening and early detection methods for medical prevention, (c) disease characteristics and prognosis, and (d) anxiety and quality of life. Decisions regarding these options must be individualized, and psychological support must be offered during the period of decision and follow-up [27] .
New therapeutic possibilities
In recent years a bulk of knowledge, particularly in breast cancer biology and clinical oncology has provided the opportunity to attack signal-transduction targets involved in cell survival, proliferation, invasion, angiogenesis, metastasis, and therapy resistance [30] . All collected data are very important for making the right choice in rational selection and validation of those relevant targets that provide the best opportunities for development of "intelligent" therapeutics [31, 32] . Although not discovered by "chips" of proteomics, these molecules represent very promising targets in breast cancer therapy. However, it is realistic to expect that both genomics and proteomics (in their methodologically improved versions) will be used to clarify at least some steps in complexes of intracellular interactions.
Targeting the enzymes involved in the control of genetic stability and chromosome segregation may prove a good strategy for breast cancer therapy. It is already known that disruption of the serine/threonine kinase Plk1 function might have clinical utility [33] . Gene Plk1, whose expression is restricted to centrosomes and the midzone of mitotic cells, is frequently overexpressed in some tumors, and it could give rise to a transformed phenotype; its constitutive overexpression transforms NIH 3T3 cells [34] . Microinjection of anti-PLK-1 antibodies into HeLa cells and normal diploid Hs68 fibroblasts results in an inhibition of centrosome maturation and a block in mitosis [35] .
A newly discovered family of human mitotic serine/threonine kinases that are required for centrosome separation and chromosome segregation have been named aurora1 and aurora2 [36] . The aurora2 gene was mapped to chromosome 20q13; a region frequently amplified in human tumors, including ovarian and breasts cancer [37, 38] . The protein, localized to centrosomes and the mitotic spindle apparatus of dividing cells, is expressed in a variety of human tumor cell lines while having limited expression in normal human tissue. Aurora2 is amplified, overexpressed, and activated in 12% of primary breast cancers [38] . Its ablation leads to growth arrest of tumor cells [39] , which makes it an attractive target for developing enzymatic inhibitors for cancer therapy [32] .
Regulation of cell survival, extension of life span, and inhibition of apoptosis is another important target for therapy. Several new contributions in this field have recently been made mainly by explaining the functions of Akt, telomerase, IGF I, and its receptor (IGFI-R).
Akt is a key survival signal protecting cells from apoptosis; its deregulation could provide a growth advantage to tumor cells. Phosphatidylinositol 3-kinase (PI3-K) activity is required for growth factor mediated activation of Akt [40] . This is the result of a direct interaction of phosphoinositides with the pleckstrin homology domain of Akt, localizing Akt to the cell membrane [41] and allowing access to 3-phosphoinositide dependent protein kinase which activates Akt by phosphorylation at Thr 308 [42] . Akt 2 is amplified and overexpressed in a subset of breast and pancreatic cancers [43] , which suggests that an inhibitor of Akt or Akt 2 might be of therapeutic benefit [44] . Altiok and colleagues [45] have recently established connections between Akt and BRCA1. It was shown that heregulins, a group of growth factors, activate ErbB-2 and initiate a cascade of events resulting in the stimulation of PI3-K pathways. Their results clearly show that Akt, the downstream target of PI3-K mediates BRCA1 phosphorylation in response to heregulin. The localization of the Akt phosphorylation site in the nuclear translocation signal of BRCA1 suggests that phosphorylation by Akt interferes with the biological activity of BRCA1.
IGF I is a major survival factor in serum that protects cells from apoptosis under a wide variety of circumstances: growth factor withdrawal in hematopoietic cells, overexpression of c-myc proto-oncogene, chemotherapy, interleukin-converting enzyme protease action, and irradiation with UV-B [46, 47, 48, 49, 50] . This molecule elicits its responses through interaction with and activation of the IGF I receptor whose activation results in phosphorylation of insulin receptor substrate I and activation of cascades of kinases, which includes PI3-K, P70 s6 kinase, and mitogen-activated protein kinase [51] . Overexpression of the IGFI-R (independently of exogenous peptides) transforms cells to a phenotype of anchorage-independent growth [52] . Cells revert to their nontransformed phenotype by blocking the action or binding of IGFs to the IGF IR [53] . Findings by our own and other groups, based on the fact that IGFs are involved in cancer development and progression, strongly support the possibility of the IGF family being good therapeutic target [54, 55] . There are two possible therapeutic approaches: (a) to block IGF synthesis/secretion and hence to reduce local or systemic IGF levels and (b) to block the interaction of IGFs with their receptors. Both strategies work in experimental therapy of breast cancer cell lines (Fig. 2) .
Telomerase is another possible target for breast cancer therapy. This is an RNA-dependent DNA polymerase that synthesizes the telomeres, guanine-rich tandem repeats at the end of chromosomes [56] . Telomeres function to protect chromosomes from degradation and inappropriate recombination. One of the survival tactics of tumors may 571 be by extending a normal cell's lifespan, which is determined by telomere length. Telomerase transcription is upregulated in breast cancer as well as in a majority human tumors, and this overexpression results in prolonged lifespan [57] . There is some evidence that telomerase could be an attractive target for drug development [32] .
Angiogenesis is another important molecular target in anticancer therapy. Quantitative assessment of angiogenesis in breast cancer is related to prognosis and one of the most important factors involved is vascular endothelial growth factor (VEGF) [39] . Investigations of the pathways regulating VEGF show marked differences in the response of VEGF to hypoxia in different breast cancer cell lines. This was mimicked by studies in vivo. Cells that have lost their ability to submit their hypoxia signal, via transcription of hypoxia-inducible factor I, grow less well in vivo than their parents, demonstrating a critical role of hypoxia in stimulating tumor growth [30] . A simplified version of cancer therapy in this field may be the use of an "intelligent drug" that would act as a specific inhibitor of VEGF at the local level [58] .
Cancer diagnostics and therapeutics have entered the molecular age. New potential cancer targets are continuously being identified by screening gene and protein expression, by dissecting the biological processes, and by comparing genomes from simple and complex organisms. 
